Search Results - "Winter, M. K."

Constitutive μ-Opioid Receptor Activity Leads to Long-Term Endogenous Analgesia and Dependence by Corder, G., Doolen, S., Donahue, R. R., Winter, M. K., Jutras, B. L., He, Y., Hu, X., Wieskopf, J. S., Mogil, J. S., Storm, D. R., Wang, Z. J., McCarson, K. E., Taylor, B. K.

“…Opioid receptor antagonists increase hyperalgesia in humans and animals, which indicates that endogenous activation of opioid receptors provides relief from…”
Get full text

Inflammation enhances Y1 receptor signaling, neuropeptide Y-mediated inhibition of hyperalgesia, and substance P release from primary afferent neurons by Taylor, B.K, Fu, W, Kuphal, K.E, Stiller, C.-O, Winter, M.K, Chen, W, Corder, G.F, Urban, J.H, McCarson, K.E, Marvizon, J.C

“…Highlights • NPY acts at Y1 receptors in the dorsal horn to decrease inflammatory hyperalgesia. • NPY inhibits substance P release from primary afferent…”
Get full text

Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution by Johnson, L.N., Winter, K.M., Reid, S., Hartkopf-Theis, T., Marks, D.C.

“…Platelets prepared in plasma can be frozen in 6% dimethyl sulfoxide (Me 2SO) and stored for extended periods at −80 °C. The aim of this study was to reduce the…”
Get full text

The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover by Johnson, L., Winter, K. M., Reid, S., Hartkopf-Theis, T., Marschner, S., Goodrich, R. P, Marks, D. C.

“…Background and Objectives  Pathogen reduction technologies (PRT) for platelets are now compatible with both plasma and platelet additive solutions (PAS). The…”
Get full text

Long‐term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation by Burghard, M (Marcella), Berkers, G (Gitte), Ghijsen, S (Sophie), Hollander‐Kraaijeveld, FM (Francis), Winter‐de Groot, KM (Karin), Ent, CK (Kors), Heijerman, HGM (Harry), Takken, T (Tim), Hulzebos, HJ (Erik)

“…Objectives To describe the long‐term effects of ivacaftor (Kalydeco®) in individuals with cystic fibrosis (CF) on body mass index (BMI), body composition (BC),…”
Get full text

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes by de Poel, E., Spelier, S., Hagemeijer, M.C., van Mourik, P., Suen, S.W.F., Vonk, A.M., Brunsveld, J.E., Ithakisiou, G.N., Kruisselbrink, E., Oppelaar, H., Berkers, G., de Winter de Groot, K.M., Heida-Michel, S., Jans, S.R., van Panhuis, H., Bakker, M., van der Meer, R., Roukema, J., Dompeling, E., Weersink, E.J.M., Koppelman, G.H., Blaazer, A.R., Muijlwijk-Koezen, J.E., van der Ent, C.K., Beekman, J.M.

“…•We implemented a high-throughput 384-wells version of the functional FIS assay to screen a large number of PDIOs for compounds that enhance CFTR function.•We…”
Get full text

Evaluation of the quality of blood components prepared using the Reveos automated blood processing system by Johnson, L., Winter, K. M., Kwok, M., Reid, S., Marks, D. C.

“…Background and Objective The Reveos automated blood processing system has been developed to combine primary and secondary processing of whole‐blood units,…”
Get full text

Understanding the effects of gamma-irradiation on potassium levels in red cell concentrates stored in SAG-M for neonatal red cell transfusion by Winter, K. M., Johnson, L., Kwok, M., Reid, S., Alarimi, Z., Wong, J. K. L., Dennington, P. M., Marks, D. C.

“…Background and Objectives Red cell transfusions, to paediatric patients, are often gamma‐irradiated to prevent transfusion‐associated graft‐versus‐host…”
Get full text

Gamma-irradiation of deglycerolized red cells does not significantly affect in vitro quality by Winter, K. M., Johnson, L., Webb, R. G., Marks, D. C.

“…Background and Objectives Red cells frozen with glycerol may require gamma‐irradiation after thawing and deglycerolization for transfusion to at‐risk patients…”
Get full text

Letter to the editor: Risk of false newborn screening after intra-uterine exposure to ETI by De Wachter, E, Davies, JC, Simmonds, NJ, Castellani, C, de Winter-de Groot, KM, Munck, A, Proesmans, M, Southern, KW, Barben, J

Get full text

Optimization of performance of Dutch newborn screening for cystic fibrosis by Bouva, MJ, Dankert-Roelse, JE, van der Ploeg, CPB, Verschoof-Puite, RK, Zomer-van Ommen, DD, Gille, JJP, Jakobs, BS, Heijnen, MLA, de Winter-de Groot, KM

“…•Until 2016, Dutch NBS for CF, as implemented in 2011, showed a sensitivity of 90%.•In 2016, NBS for CF algorithm was modified, resulting in a sensitivity of…”
Get full text

Measurement of nasal nitric oxide: evaluation of six different sampling methods by De Winter-de Groot, K. M., Van Der Ent, C. K.

“…ABSTRACT Background  Specific guidelines are developed for the measurement of bronchial FENO, however, nasal nitric oxide (nNO) measurement is not standardised…”
Get full text

Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males by Aalbers, B.L., Hofland, R.W., Bronsveld, I., de Winter-de Groot, K.M., Arets, H.G.M., de Kiviet, A.C., van Oirschot-van de Ven, M.M.M., Kruijswijk, M.A., Schotman, S., Michel, S., van der Ent, C.K., Heijerman, H.G.M.

“…•Women compared to males have a larger sweat chloride response to lumacaftor/ivacaftor treatment.•The basis of this sex difference is yet unexplained.•Sweat…”
Get full text

Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV1 ≥ 90% predicted at baseline by Aalbers, B.L., de Winter-de Groot, K.M., Arets, H.G.M., Hofland, R.W., de Kiviet, A.C., van Oirschot-van de Ven, M.M.M., Kruijswijk, M.A., Schotman, S., Michel, S., van der Ent, C.K., Heijerman, H.G.M.

“…•CF patients starting lumacaftor/ivacaftor with ppFEV1 ≥ 90 do not respond to treatment in ppFEV1.•There are however beneficial effects on BMI and exacerbation…”
Get full text

Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids by Zomer-van Ommen, D.D, Vijftigschild, L.A.W, Kruisselbrink, E, Vonk, A.M, Dekkers, J.F, Janssens, H.M, de Winter-de Groot, K.M, van der Ent, C.K, Beekman, J.M

“…Abstract Premature termination codon read-through drugs offer opportunities for treatment of multiple rare genetic diseases including cystic fibrosis. We here…”
Get full text

A bioassay using intestinal organoids to measure CFTR modulators in human plasma by Dekkers, R, Vijftigschild, L.A.W, Vonk, A.M, Kruisselbrink, E, de Winter-de Groot, K.M, Janssens, H.M, van der Ent, C.K, Beekman, J.M

“…Abstract Treatment efficacies of drugs depend on patient-specific pharmacokinetic and pharmacodynamic properties. Here, we developed an assay to measure…”
Get full text

The impact of chest computed tomography and chest radiography on clinical management of cystic fibrosis lung disease by Bortoluzzi, Carla F, Pontello, Eleonora, Pintani, Emily, de Winter-de Groot, Karin M, D'Orazio, Ciro, Assael, Baroukh M, Hunink, M.G. Myriam, Tiddens, Harm A.W.M, Caudri, Daan

“…AbstractBackgroundRecent standards of care mention chest radiography (CR) but not chest computed tomography (CT) in routine annual follow-up of children with…”
Get full text

Constitutive [mu]-Opioid Receptor Activity Leads to Long-Term Endogenous Analgesia and Dependence by Corder, G, Doolen, S, Donahue, R R, Winter, M K, Jutras, B L, Y. He, X. Hu, Wieskopf, J S, Mogil, J S, Storm, D R, Wang, Z J, McCarson, K E, Taylor, B K

“…The properties and functions of µ-opioid receptors have been studied intensively with respect to the binding of endogenous or exogenous ligands. However, much…”
Get full text

Dieldrin reduces male production and sex ratio in Daphnia galeata mendotae by Dodson, S I, Merritt, C M, Torrentera, L, Winter, K M, Tornehl, C K, Girvin, K

“…We used the sex ratio of neonate Daphnia, as well as the more standard endpoints of adult survivorship and fecundity and neonatal morphology, as an assay for…”
Get more information

Antibiotic misuse in respiratory tract infections in children and adultsa prospective, multicentre study (TAILORED Treatment) by van Houten, C. B., Cohen, A., Engelhard, D., Hays, J. P., Karlsson, Roger, Moore, Edward R.B., Fernandez, D., Kreisberg, R., Collins, L. V., de Waal, W., de Winter-de Groot, K. M., Wolfs, T. F. W., Meijers, P., Luijk, B., Oosterheert, J. J., Heijligenberg, R., Sankatsing, S. U. C., Bossink, A. W. J., Stubbs, A., Stein, M., Reisfeld, S., Klein, A., Rachmilevitch, R., Ashkar, J., Braverman, I., Kartun, V., Chistyakov, I., Bamberger, E., Srugo, I., Odeh, M., Schiff, E., Dotan, Y., Boico, O., Navon, R., Friedman, T., Etshtein, L., Paz, M., Gottlieb, T. M., Pri-Or, E., Kronenfeld, G., Simon, E., Oved, K., Eden, E., Bont, L. J.

“…Respiratory tract infections (RTI) are more commonly caused by viral pathogens in children than in adults. Surprisingly, little is known about antibiotic use…”
Get full text